Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA
Authors:
- Patricia Vella BonannoPBPatricia Vella Bonanno
- Anna BucsicsABAnna Bucsics
- Steven SimoensSSSteven Simoens
- Antony P MartinAMAntony P Martin
- Wija OortwijnWOWija Oortwijn
- Jolanta GulbinovičJGJolanta Gulbinovič
- Celia RotheCRCelia Rothe
- Angela TimoneyATAngela Timoney
- Alessandra FerrarioAFAlessandra Ferrario
- Mohamed GadMGMohamed Gad
- Ahmed SalemASAhmed Salem
- Iris HoxhaIHIris Hoxha
- 15 February 2019
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 19 (3) , 251-261
Abstract
Introduction: In January 2018 the European Commission published a Proposal for a Regulation on Health Technology Assessment (HTA): ‘Proposal for a Regulation on health technology assessment and amending Directive 2011/24/EU’. A number of stakeholders, including some Member States, welcomed this initiative as it was considered to improve collaboration, reduce duplication and improve efficiency; there were however a number of concerns including its legal basis, the establishment of a single managing authority, the preservation of national jurisdiction over HTA decision making and the voluntary/mandatory uptake of joint assessments by Member States. Areas covered: This paper presents the consolidated views and considerations on the original Proposal as set by the European Commission of a number of policy makers, payers, experts from pricing and reimbursement authorities and academics from across Europe. Expert commentary: The Proposal has since been extensively discussed at Council and while good progress has been achieved, there are still divergent positions. The European Parliament gave a number of recommendations for amendments. If the Proposal is approved, it is important that balanced, improved outcome is achieved for all stakeholders. If not approved, the extensive contribution and progress attained should be sustained and preserved, and the best alternative solutions found.Keywords
Funding Information
- paper
This publication has 55 references indexed in Scilit:
- Understanding the Role and Evidence Expectations of Health Technology Assessment and Coverage/Payer Bodies: What Are They Looking for, and How and Why Does This Differ From What Regulators Require?Therapeutic Innovation & Regulatory Science, 2014
- Inequities in access to biologic and synthetic DMARDs across 46 European countriesAnnals of the Rheumatic Diseases, 2014
- MAPPING OF HEALTH TECHNOLOGY ASSESSMENT IN SELECTED COUNTRIESInternational Journal of Technology Assessment in Health Care, 2013
- The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML expertsBlood, 2013
- Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugsFrontiers in Pharmacology, 2013
- Cost-Effectiveness Assessment of Orphan DrugsApplied Health Economics and Health Policy, 2012
- Differences in external price referencing in Europe—A descriptive overviewHealth Policy, 2011
- A history of health technology assessment at the European levelInternational Journal of Technology Assessment in Health Care, 2009
- Insight into recent reforms and initiatives in Austria: implications for key stakeholdersExpert Review of Pharmacoeconomics & Outcomes Research, 2008
- CONCLUSIONInternational Journal of Technology Assessment in Health Care, 2000